AlphaMaven AlphaMaven

Google’s Isomorphic Labs Raises $5 Billion Series C From Greenoaks And Sequoia Capital

Reported by Officechai
Nov 17, 2026· 3 min read
Save Post LinkedIn Email
Key Takeaways
  • • Isomorphic Labs, the Alphabet-owned AI drug design company founded by Google DeepMind CEO Demis Hassabis, closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, according to Hassabis's announcement on X.
  • • The round was oversubscribed, with Andreessen Horowitz (a16z) and other new investors joining, while Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated.
  • • The raise more than doubles the company's $2.1 billion Series B from May 2026, lifting total external funding to roughly $7.7 billion; Isomorphic did not disclose a valuation, though Bloomberg had reported talks at roughly $50 billion.
  • • Proceeds will scale the IsoDDE drug design engine, expand the drug candidate pipeline, and fund AI-first translational and clinical development, with preclinical oncology and immunology results cited.
  • • Isomorphic has yet to put a drug into the clinic, so the next key milestone is whether its first AI-designed candidates enter human trials.
Summary
Isomorphic Labs has closed a $5 billion Series C funding round co-led by Greenoaks and Sequoia Capital, according to an announcement by founder Demis Hassabis on X. Hassabis said the funding would accelerate the company's mission to "Solve All Disease." The round was oversubscribed. Andreessen Horowitz (a16z) and several other new investors joined, while Alphabet continued to invest significantly. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated. Isomorphic did not disclose a valuation, although Bloomberg had reported earlier this month that the company was in talks to raise around $5 billion at a valuation of roughly $50 billion.

The round follows a rapid fundraising sequence. Isomorphic raised a first external round of $600 million led by Thrive Capital in March 2025, followed by a $2.1 billion Series B, also led by Thrive, in May 2026. The Series C more than doubles that figure and brings total external funding to around $7.7 billion.

Isomorphic says it will use the capital to scale IsoDDE, its proprietary drug design engine, a set of foundational simulation models spanning multiple therapeutic areas and drug modalities, supported by in-house AI agents. Funds will also go toward its pipeline of AI-designed drug candidates, a partner ecosystem around disease biology, AI-led bioengineering infrastructure, and translational and clinical development capabilities. The company reports positive preclinical results in oncology and immunology, both internally and with partners, and expects these to lead to clinical entry. It has partnerships with Novartis, Eli Lilly and Johnson & Johnson. Max Jaderberg, President of Isomorphic Labs, said the company is making repeatable scientific advances that translate into better molecular profiles.

Isomorphic was spun out of DeepMind in 2021, building on AlphaFold, which earned Hassabis and John Jumper the 2024 Nobel Prize in Chemistry. The company co-developed AlphaFold 3 with Google DeepMind, and its IsoDDE engine is reported to significantly outperform AlphaFold 3 on difficult benchmarks such as predicting drug binding to novel protein pockets. However, the company acknowledges that a protein structure is not a medicine. Hassabis had predicted the first AI-created drugs would be in clinics by the end of 2025, a timeline that has slipped. Isomorphic said last year it was "very close" to starting human trials but has not yet dosed a drug in the clinic, and still describes its first programs as moving "toward" trials.

The raise places Isomorphic among the best-funded AI drug discovery companies, a scale more typical of frontier AI labs than of pre-clinical biotech. The investment reflects the thesis that AI can shift most of the discovery process from the wet lab to computation, compressing timelines that traditionally exceed a decade and cost billions of dollars. The next milestone to watch is whether Isomorphic's first AI-designed candidates enter human trials and how they perform there.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Officechai Google’s Isomorphic Labs Raises $5 Billion Series C From Greenoaks And Sequoia Capital